Background: Majority of gastrointestinal stromal tumours (GISTs) are characterised by KIT-immunopositivity and the presence of KIT/platelet-derived growth factor receptor alpha (PDGFRA) activating mutations.
introduction
Gastrointestinal stromal tumours (GISTs) are distinctive KITexpressing tumours of the gastrointestinal tract [1] , characterised by gain of function mutations in either KIT or platelet-derived growth factor receptor alpha (PDGFRA), found in 80%-85% of cases [2] [3] [4] [5] [6] [7] .
Many types of KIT and PDGFRA mutations have been described in GISTs, but their prognostic and predictive significance is still under investigation [8] . Deletions in KIT exon 11, particularly those involving codons 557 and/or 558, are associated with high metastatic risk and are reported as an independent adverse prognostic factor [9, 10] . Single KIT exon 11 substitutions are associated with longer relapse-free survival (RFS) and overall survival [8] . Conversely, the KIT exon 9 duplications, occurring almost exclusively in intestinal tumours, have been associated with malignant behaviour [11, 12] . Homo-/ hemizygous KIT mutations were reported to associate with tumour liver metastasis and poor clinical outcome of the disease [13] . PDGFRA-mutated GISTs are typically characterised by a low mitotic count and low malignant potential, and in majority may represent clinically benign tumours [14, 15] .
The mutational status of KIT and PDGFRA is also a significant predictive factor for response to imatinib (GlivecÒ; Novartis, Basel, Switzerland). The objective response to treatment is the best in patients whose tumours harbour KIT exon 11 mutations, while patients with KIT exon 9 duplications respond worse and may require higher dose of the drug. Primary resistance to imatinib is mainly observed in the subset of patients carrying PDGFRA p.D842V substitution [16, 17] . Only recently has imatinib been approved in Europe and the United States for the adjuvant treatment of GISTs in patients with 'significant' risk of relapse. The current risk criteria are based on tumour size, mitotic activity and the localisation of the primary lesion [7, 18] . Some studies also emphasised patients' gender as a prognostic factor for predicting recurrence after resection of primary GISTs [19] . It is still debatable whether the mutational analysis should be included in the diagnostic workup and results should be considered as an additional prognostic factor [18] .
The aim of this study was to determine the frequency of KIT and PDGFRA mutations in the large series of GISTs and to estimate the contribution of different types of mutations in prognostic parameters.
materials and methods tumour material and patients' clinical data
Surgical specimens of imatinib-naive GISTs from the period 1999-2009 were prospectively included in the Polish Clinical GIST Registry without further data selection. Clinicopathologic data were supplemented by a retrospective review of all available medical and histopathological records from 17 referring hospitals. The RFS was defined as the time between the date of surgery and the date of relapse. At the date of cut-off, the median time since diagnosis was 3.8 years (range 0.4-27.6 years).
Follow-up information was obtained during regular outpatient visits or by phone with the patient and/or the referring physician. Postoperative follow-up consisted of physical examination and routine imaging investigations (computed tomography of the abdominal cavity/the pelvis and chest X-ray) as was described previously [19] . In high-/intermediaterisk groups, thorough standard examination was carried out, i.e. every 3-4 months during the first 2 years, every 4 months in the third year, and then every 6 months. In low/very low-risk groups, the patients were followed-up every 6-12 months in accordance with Polish national guidelines [20] . The incidence of other malignant (metachronous or synchronous) tumours was also recorded (10% rate, as was presented previously [21] ).
histopathological evaluation
For resected GIST, the largest tumour diameter and mitotic count per 50 high-power fields (HPF) were evaluated in each case, as recommended by international criteria. Initial GIST staging was based mainly on histopathological data from referring Department of Pathology and preoperative imaging (mainly computed tomography assessment). The potential risk for malignancy was evaluated using National Comprehensive Cancer Network (NCCN) criteria, based on Miettinen and Lasota's [7] AFIP stratification [18] .
Histopathological examination was carried out on formalin-fixed paraffinembedded (FFPE) tissue. Immunohistochemistry was carried out with anti-CD117 (A-4502, polyclonal, dilution 1/250; DAKO, Golstrup, Denmark).
molecular analysis
Mutational analysis was carried out on genomic DNA isolated from FFPE tissues, using macrodissection and standard procedure. KIT exons 9, 11, 13, and 17 and PDGFRA exons 12, 14, and 18 were amplified. Genomic sequences were obtained from Ensembl database (www.ensembl.org; release 57): KIT (ENST00000288135) and PDGFRA (ENST00000257290). Specific primers were designed using Primer3 software (http://frodo.wi.mit.edu/ primer3/) (sequences available on request). Amplicons were prescreened using denaturing high performance liquid chromatography (WAVE System; Transgenomic, Omaha, NE). Fragments with abnormal profile were bidirectionally sequenced using BDT v3.1 and ABI PRISM 310 Genetic Analyser (Applied Biosystems, Foster City, CA). Mutation nomenclature followed the recommendations of the Human Genome Variation Society (www.hgvs.org).
statistical analysis
For univariate analysis, chi-square or Fisher's exact tests and Mann-Whitney test were used to compare categorical and continuous variables, respectively. Survival analysis was carried out with Kaplan-Meier method, compared by log-rank test. All patients without evidence of relapse at the time of the last clinical visit were censored. Cox's proportional hazard model was used for the multivariate analysis. The following parameters were analysed: age at diagnosis, gender, tumour localisation, mitotic index (MI), size and NCCN grade. The value of P < 0.05 was interpreted as statistically significant. Analyses were carried out with R 2.10.1 (http://www.R-project.org) and STATISTICA v.9 software package (StatSoft Inc, Tulsa, OK).
results

patients' characteristics
Overall, imatinib-naive GIST specimens from 427 patients were available for the study, which included 222 men and 205 women [mean age 59.18 6 13.77 (range 9-93 years)]. The cohort included seven paediatric GISTs (range 9-17 years). Tumours were localised in the stomach (52.8%), small intestine (26.8%), intra-abdominally (5.5%), colon (3.8%), duodenum (3.3%), and 7.8% had other localisation. The median tumour size was 8 cm (range 0.8-23 cm). By immunohistochemistry, 96% of tumours were positive for CD117 antigen (KIT). The clinicopathologic data were missing for 27 patients (6.3%). A detailed clinical and pathological characteristic of the analysed group is presented in Table 1 .
genotype analysis
KIT or PDGFRA mutations were found in 351 (82.2%) cases, while in 76 specimens no mutation was detected, including all seven paediatric cases. In total, 296 (69.3%) of analysed samples had KIT mutation, mostly in exon 11 (n = 261; 61.1%) or exon 9 (n = 31; 7.3%). PDGFRA was mutated in 55 specimens (12.9%). Distribution of tumours according to the type/site of mutation is presented in Table 2 .
The most frequent types of KIT exon 11 mutations were isolated deletions (n = 145; 34%), substitutions (n = 66; 15.5%) and duplications (n = 30; 7.0%) ( Table 2 ). The most frequently involved codons of KIT exon 11 were 557 (in 43% of KIT exon 11 mutants), 558 (38%) and 559 (34%). The detailed frequency of codon involvement is presented in Figure 1 . Deletions were always in-frame and consisted of 3-63 nucleotides. They were clustered in the 5#-end of exon 11 in 124 cases. The most common deletion p.W557_K558del was found in 32 tumours (7.5%). In addition, we identified 67 (15.7%) larger deletions involving codons 557 and/or 558. Single substitutions mostly affected codons 559 (n = 21; p.V559D, p.V559A, p.V559G), 557 (n = 21; p.W557G, p.W557R), 560 (n = 14; p.V560D) and 576 (n = 7; p.L576P) (Figure 1 ). There were 30 internal tandem duplications and all but one involved 3#-end of exon 11. The length of duplication varied from 6 to 48 bp, with codons 576-579 being most commonly involved. In 17 cases (4%) with detectable KIT exon 11 mutation, no wild-type allele was found, indicating a homo-/hemizygous status. Among them, there were 12 deletions, four substitutions and one complex mutation. Six tumours (1.4%) revealed deletion affecting intron 10/exon 11 junction that included 3-8 bp of intron 10 and resulted in loss of the normal splice acceptor site, causing consistent p.K550_K558del.
Mutation in KIT exon 9 (all p.A502_Y503dup) was found in 31 cases (7.3%), and two cases revealed mutation in tyrosine kinase domain 1 (exon 13) both p.K642E. Two mutations involving the kinase activation loop of KIT (exon 17) included p.N822K and p.N822H.
Among PDGFRA mutants, most changes were identified in exon 18 (n = 51; 11.9%), including 35 cases (8.2%) with substitution p.D842V, and 16 tumours (3.7%) with in-frame deletion or deletion/insertion of different length (9-15 bp). Moreover, three cases (0.7%) showed substitution in exon 14 of PDGFRA (p.N659K), and one (0.2%) revealed deletion in exon 12 (p.S566_E571delinsR).
Overall, PDGFRA p.D842V (n = 35), KIT p.W557_K558del (n = 32) and KIT p.A502_Y503dup (n = 31) were the most frequent mutations in the analysed group.
mutations and clinicopathologic features
Detailed distribution of tumours according to the type of mutation and clinicopathologic features is presented in Table 3 . The majority of KIT mutants displayed spindle morphology, while PDGFRA mutants showed mainly epithelioid or mixed phenotype (76% versus 58%; P < 0.001). Moreover, majority of tumours with PDGFRA mutations were of gastric origin (91%), in contrast to KIT mutants (45%; P < 0.001). In addition, tumours carrying PDGFRA mutations demonstrated frequently low MI (<5/50 HPF in 70% of cases; P < 0.001), they were more often categorised as of (very) low risk when compared with KIT mutant GISTs (49% versus 26%; P = 0.001). When tumours with KIT exon 9 and exon 11 mutations were compared, the former were more frequently larger ( ‡10 cm in 56% versus 34% of samples; P = 0.044), and more often had intestinal localisation (87% versus 38%; P < 0.001). Over 80% of KIT exon 9 mutants and 57% of KIT exon 11 mutants were classified as NCCN high-risk tumours (P = 0.021) ( Table 3 ). The detailed analysis of different subtypes of KIT exon 11 mutations revealed that deletions were more commonly detected in tumours with higher mitotic activity (>10/50 HPF in 41% versus 25%; P < 0.001), higher tumour size (>5 cm in 85% versus 59%; P = 0.002) and classified as NCCN high risk (71% versus 41%, P = 0.001).
Deletions involving KIT codons 557 and/or 558 are thought to contribute to patients' poor prognosis. They were more often found in spindle type GISTs (73%), in tumours of size >5 cm (89%) and were equally distributed among tumours originating from stomach or intestine. Conversely, when comparing with deletions not encompassing codons 557/558, they were more often identified in tumours with high MI (>10/50 HPF in 47% versus 29%; P = 0.024) and in tumours classified as high risk (80% versus 53%; P = 0.005).
KIT exon 11 duplications were present in gastric tumours (26 out of 30), displaying the median size of 6 cm (range 1.8-30 cm) and 5/50 HPF median MI (range 0-30/50 HPF) ( Table 3) .
mutations and patients' clinical outcome
All patients with localised primary tumours were treated surgically (n = 378, 88.5%), while 49 (11.5%) tumours were metastatic at diagnosis. Follow-up data were available from 285 patients; median follow-up time was 33 months (range: 0.8-540 months) and median RFS for the whole group was 12 months (range: 0.3-210 months). The disease progression was observed in 139 out of 256 (54.2%) patients with primary, localised disease, for whom the follow-up data were available. The median RFS for this group was 10 months (range: 1-209 months).
In univariate analysis, 5-year RFS rate was significantly higher in women (37.9%; P = 0.028) and in patients with tumours localised in the stomach (46.3%; P < 0.001). Moreover the better 5-year prognosis correlated with tumour smaller size of £5 cm (62.7%; P < 0.001), with lower MI £5/50 HPF (60%; P < 0.001), and classified as of (very) low/moderate risk (70.2%; P = 0.006) (Table 4, Figure 2A and B).
There was no significant difference in 5-year RFS rate between patients with KIT exon 9 and exon 11 mutations (Table 4, Figure  2C ). Conversely, better 5-year RFS rate was observed in the presence of KIT exon 11 substitutions or duplications than deletions (50.7% and 40%, respectively; P = 0.007) (Table 4) , which was confirmed by log-rank test (P = 0.001) ( Figure 2D ).
Patients with GISTs bearing deletions involving KIT codons 557 and/or 558 had worse 5-year RFS rate (23.8%) than those with any other KIT exon 11 mutations (41.8%; P < 0.001) or when only deletions not involving codons 557/558 were analysed (33.3%; P = 0.007). Similar significant results were obtained using log-rank test when comparing RFS curves (P < 0.001 and P = 0.003, respectively) ( Figure 2E and F) . Also statistical significance was reached when comparing Kaplan-Meier curves of patients harbouring 557 and/or 558 deletion with any other genotype, including 'wild-type' cases ( Figure 2G ). Tumour localisation (gastric versus intestinal) did not influence outcome in patients with 557/558 deletion ( Figure 2H ). When analysing tumours with the three most common types of mutations, i.e. PDGFRA-D842V, KIT-W557_K558del, KIT-A502_Y503dup, and with all KIT exon 11 point mutations (KIT11_PM) as a fourth group, the incidence of metastasis reported at diagnosis was higher in carriers of KITW557_K558del (10/32; 31.2%) and in KIT-A502_Y503dup (7/31; 22.6%) than in PDGFRA-D842V (3/35; 8.6%) or KIT11_PM 
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(1/66; 1.5%). Also median RFS in patients with substitutions, either in PDGFRA (12.95 months) or in KIT (12.9 months), was longer than in patients with deletion KIT-W557_K558 (9.9 months) or with KIT-A502_Y503dup (7.6 months). In addition, there was statistically significant difference (P = 0.007) between RFS of these groups by log-rank test ( Figure 2I ). Cox's proportional hazard model analysis showed 70% lower risk for patients with PDGFRA mutations [hazard ratio (HR) = 0.298, 95% confidence interval (CI) 0.147-0.602; P = 0.001], 59% for KIT11_PM (HR = 0.416, 95% CI 0.246-0.704; P = 0.001) and 53% for KIT exon 11 duplications (HR = 0.467, 95% CI 0.297-0.736; P = 0.001) when compared with KIT exon 11 deletion involving codons 557/558. The same tendency was observed when other tumour features (gender, size, MI localisation, NCCN risk stratification) were added to the Cox model, but without statistical significance.
The majority of cases with homo-/hemizygous KIT exon 11 mutations (11/17) and all but one with deletion affecting intron 10/exon 11 junctions belonged to high-risk group or were overtly malignant at the time of diagnosis.
discussion
In this study, we have examined the spectrum, frequency and prognostic significance of KIT and PDGFRA mutations in patients with GISTs registered in the Polish Clinical GIST Registry. In literature KIT/PDGFRA mutational status provides some indications of prognostic outcome, but owing to studies on relatively small groups the relevance is still debatable. To our knowledge, the presented study is the largest available series of imatinib-naive GISTs, with detailed genotype description, which has been analysed for the prognostic significance of the KIT/PDGFRA mutations.
The overall mutation rate in our study was 82.2%, which is comparable to frequencies observed in a population study from Norway (85.4%) and in two phase III imatinib clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) (86.2%) and the United States (84.6%) [16, 17, 22] ; the frequency rate is a little lower than in Icelandic population study (92.9%) [23] . In our cohort, KIT exon 11 and 9 mutants accounted, respectively, for 61.1% and 7.3% of Figure 2 . Kaplan-Meier estimate of the probability of relapse-free survival (RFS) in gastrointestinal stromal tumours patients with different mitotic index categories (A); according to National Comprehensive Cancer Network risk groups (B); KIT exon 9 versus KIT exon 11 mutations (C); substitutions versus deletions versus internal tandem duplications in KIT exon 11 (D); deletions involving codons 557 and/or 558 versus all other KIT exon 11 mutations (E); deletions involving codons 557 and/or 558 versus all other KIT exon 11 deletions without codons 557 and/or 558 involvement (F); deletions involving codons 557 and/or 558 versus all other genotypes (including 'wild type') (G); deletions involving codons 557 and/or 558 versus deletions involving codons 557 and/or 558 in tumours with gastric versus intestinal localisation (H); W557_K558del versus p.A502_Y503dup versus p.D842V and versus all KIT exon 11 substitutions (KIT11_PM) (I). RFS between groups is compared using the log-rank test. Circles represent complete observations and crosses symbolise censored ones.
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GISTs, which is in agreement with a Norwegian populationbased study (75.3% versus 5.6%) [22] and with the French MolecGIST series (59.1% versus 5.9%) [24, 25] (Table 2) . Conversely, Debiec-Rychter et al. [16] showed the similar frequency of KIT 11 mutations (65.8%), while exon 9 frequency was significantly higher (15.4%) , and in the study of Heinrich et al. [17] , those values were 72.9% and 8.2%, respectively. Those two later studies were conducted within phase III clinical trials, therefore the discrepancy may reflect a difference in mutation profile observed due to referral material, with more overtly malignant GISTs enrolled to clinical trials.
Tumours with KIT exon 11 deletions have been reported to be more clinically aggressive than those with substitutions [26, 27] . Wardelmann et al. [9] showed that deletion of W557 and K558 was associated with metastatic behaviour. Several studies pointed out that this deletion represents significant adverse factor for patients' outcome [10] . The recent study by Martin-Broto et al. [28] demonstrated that the predictive value of deletion of 557/558 for recurrence is limited to the first 4 years after surgery. In our study, the isolated p.W557_K558 deletion was disclosed in 32 (7.5%) GISTs, and codons 557 and/or 558 were lost due to the larger deletion in 67 (15.7%) additional samples. Deletions that affected codons 557/558 were more often found in tumours with higher MI (75% with >5/50 HPF), of larger size (88%, >5 cm), and stratified as high-risk tumours (80%). They characterised patients with lower 5-year RFS rate (23.8%) when compared with patients with any other KIT exon 11 mutations (41.8%, P < 0.001), but also with other exon 11 deletions that have not involved codons 557/558 (33.3%, P = 0.007), confirmed by log-rank test for RFS curves. Interestingly, the prevalence of p.W557_K558del is similar in a populationbased study (5.3%) [25] , in the material from EORTC 62005 clinical trial (6.9%) [16] , and in the current study (7.5%).
The discrepancy in the frequency of KIT exon 11 substitutions between population-based studies and clinical trials material is being observed; the former estimates the rate as 19.1%-28.6% [22, 23] , while in phase III studies, they are as low as 1.6%-1.86% [16, 17] . Since they are underrepresented in the cohorts of patients enrolled for those trials, in which patients with only advance tumours were included, this may support the thesis that KIT exon 11 mutants with single nucleotide substitutions are clinically less aggressive tumours. In the present study, the frequency of KIT exon 11 substitutions was 15.5%. Tumours with substitutions were characterised by low mitotic activity and average size <5 cm. Such a phenomenon was also previously observed in the Norwegian population study, where the association between the presence of point mutation and low mitotic count was noted, although it only approached statistical significance (P = 0.062) [22] . Of note, Singer et al. [29] reported 89% rate of 5-year RFS in nine patients with KIT exon 11 substitutions. In our study, patients with KIT substitutions also had better 5-year RFS rate (50.7%) than those with KIT deletions or duplications (28.1% and 40.0%, respectively).
Duplications in KIT exon 11 are associated with gastric tumour location and female gender [30] . Our study has confirmed this association since 26 out of 30 GISTs with 3#-end internal tandem duplications were of gastric origin and 21 of them were found in women. Benign clinical outcome has also been observed for these patients.
Lack of wild-type allele was found in 17 cases (4%) with detectable KIT exon 11 mutations, indicating a homo-/ hemizygous KIT status. The majority of those cases (11/17) had high risk of metastatic disease or were already disseminated, which would confirm previously reported findings that the presence of homozygous KIT exon 11 mutations is associated with malignant course of disease [13] .
In our series, six tumours (1.4%) revealed deletion affecting intron 10/exon 11 junction, resulting in consistent p.K550_K558 deletion. Corless et al. [31] observed such deletions with almost twice higher frequency (2.6%). In our study, all but one tumour were characterised as high risk or were overtly malignant at the time of diagnosis, which may suggest more aggressive behaviour of tumours with such deletion.
Previous studies have shown 5.6%-17.8% of GISTs with KITA502_Y503dup [11, 12, 16, 17, 22, 23] . The highest frequency had been observed in phase III EORTC clinical trial; this discrepancy may be due to the specific characteristics of patients enrolled for the trial. The presence of mutation in KIT exon 9 has been linked to intestinal tumour location and malignant outcome [11, 12] . Similarly, in our study, KIT-A502_Y503dup mutation was associated with small intestine origin (27 out of 31 tumours) and malignant behaviour. Interestingly, it was found more frequently in male patients (21 out of 31).
KIT tyrosine kinase domain mutations involving exons 13 and 17 were found in two cases each. This observation supports the notion that these have been uncommon mutations [32] .
In the present study, PDGFRA was mutated in 12.9% of cases. Those tumours were almost exclusively of gastric origin (91%), which is in agreement with previous reports [14, 26] . There is a large variation between the frequencies of those mutations in different studies, which can be at least partially explained by material selection bias. Corless et al. [15] estimated the frequency at 7.2%, while Miettinen et al. [26] established the frequency as high as 22.6% in a gastric series of GISTs. In contrast, in two phase III imatinib trials, the frequency was as low as 2.65% and 1.6% [16, 17] . This difference probably reflects the low representation of PDGFRAmutated GISTs in clinical trial material due to their largely benign overall clinical behaviour [14, 26] .
Multivariate analysis revealed that patients with mutations involving PDGFRA, and KIT exon 11 substitutions or duplications have lower risk of 5-year relapse when compared with patients with KIT deletions involving codons 557/558 (P = 0.001). That is in line with the finding that those 'lower-risk' mutations are less frequently identified in the material from clinical trials [16, 17] , and with the notion that they characterise a more benign subgroup of tumours. A similar but not significant tendency was observed when other tumour features were added to the Cox model. In order to reach the significance, larger groups with 'lowrisk' mutations, more homogenous in terms of tumour localisation, size and MI are required.
In summary, we conclude that KIT/PDGFRA mutations are very frequent molecular event in GISTs and the type of mutation has a prognostic significance for patients' outcome. Our finding contributes to the identification of a subset of GIST patients with lower risk of relapse, for which the use of adjuvant imatinib treatment might be controversial.
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